Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03520101). This is a study registration, not published results. Lead sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 102 participants (ACTUAL). Conditions: Aortic Valve Stenosis, Regurgitation, Aortic, Prosthesis Failure. Interventions: PROCEDURE: TAVI_ViV procedure with Edwards valve; PROCEDURE: TAVI_ViV procedure with CoreValve system. Primary outcome measures: Rate of prothesis-patient mismatch (PPM) (valve performance) , 30 days; Residual transvalvular gradient , 30 days. Brief summary: The treatment with transcatheter aortic valve implantation (TAVI) of patients with small (≤23mm) surgical bioprostheses remains a challenge due to the increased transvalvular residual gradients and high rates of severe prosthesis-patient mismatch (PPM) following the procedure.